(Q53112373)

11 May 2018

title

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. (English)

1 reference

11 May 2018

0 references

6

Dirk Hose

1 reference

11 May 2018

10

Hartmut Goldschmidt

1 reference

11 May 2018

author name string

Leopold Sellner

1

1 reference

11 May 2018

Christiane Heiss

2

1 reference

11 May 2018

Axel Benner

3

1 reference

11 May 2018

Marc S Raab

4

1 reference

11 May 2018

Jens Hillengass

5

1 reference

11 May 2018

Nicola Lehners

7

1 reference

11 May 2018

Gerlinde Egerer

8

1 reference

11 May 2018

Anthony D Ho

9

1 reference

11 May 2018

Kai Neben

11

1 reference

11 May 2018

language of work or name

English

0 references

publication date

10 April 2013

1 reference

11 May 2018

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

11 May 2018

volume

119

1 reference

11 May 2018

issue

13

1 reference

11 May 2018

page(s)

2438-2446

1 reference

11 May 2018

Autologous hematopoietic stem-cell transplantation for multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

The Arkansas approach to therapy of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Durable remission with salvage second autotransplants in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

European perspective on multiple myeloma treatment strategies: update following recent congresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.28104

1 reference

7 January 2021

Carfilzomib in multiple myeloma: gold, silver, or bronze?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28104

7 January 2021

Identifiers

DOI

10.1002/CNCR.28104

1 reference

11 May 2018

1 reference

11 May 2018